~~<i id='DB01215D8F'><strike id='DB01215D8F'><tt id='DB01215D8F'><pre id='DB01215D8F'></pre></tt></strike></i>~~

Home» knowledge» fashion

fashion

author：explore 2025-10-01 04:33:19 Page View：48929

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ProMED sees offers of support, but its future remains unclear
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Wikipedia

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

5:32Fromleft,SenateJudiciaryCommitteerankingmemberSen.LindseyGraham,ChairmanRichardDurbinandSen.Dian

Guidelines to prevent youth baseball injuries need more muscle

Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

Hospitals struggle to profit from CAR

MedicaregenerallypaysfarmoreforCAR-Tdrugsthatareadministeredinoutpatientdepartmentsthanitdoesforinpa